
## INHIBITION OF LYSOSOMAL GLYCOSIDASES BY MULTIMERIC PRESENTATIONS OF PYRROLIDINE-BASED IMINOSUGARS

Macarena Martínez-Bailén<sup>a</sup>, <u>Ana T. Carmona</u><sup>a</sup>, Camilla Matassini<sup>b</sup>, Francesca Cardona<sup>b</sup>, Atsushi Kato<sup>c</sup>, Inmaculada Robina<sup>a</sup>, Antonio J. Moreno-Vargas<sup>a</sup>

<sup>a</sup> Department of Organic Chemistry, Faculty of Chemistry, University of Seville, 41012-Seville, Spain
<sup>b</sup> Dipartimento di Chimica "Ugo Schiff", Università degli Studi di Firenze, 50019 Sesto Fiorentino (FI), Italy
<sup>c</sup> Department of Hospital Pharmacy, University of Toyama, Toyama 930-0194, Japan

Multivalency is a phenomenon broadly studied in the field of carbohydrate-protein interactions [1]. Recently, this concept has been applied in the field of glycosidase inhibition as a promising alternative to prepare potent inhibitors for the treatment of diseases involving enzymatic hydrolysis of glycosidic bonds in carbohydrates [2].

The aim of the present work was to study if the multimeric presentation of pyrrolidinetriazole inhitopes onto several platforms influences the inhibition properties towards human lysosomal  $\beta$ -glucocerebrosidase and  $\alpha$ -galactosidase A, enzymes involved in Gaucher and Fabry diseases. For the synthesis of the multivalent compounds we have used the Cu(I)-catalyzed azide-alkyne cycloaddition reaction (CuAAC) between several alkynyl functionalized scaffolds and three pairs of epimeric pyrrolidine derived azides.



Some of the compounds showed relevant inhibition towards  $\alpha$ -galactosidase A and constitute the first examples of a remarkable multivalent effect in the inhibition of this enzyme.

[2] For reviews, see: (a) Gouin, S. G. *Chem. Eur. J.* **2014**, *20*, 11616-11628. (b) Zelli, R.; Longevial, J.-F.; Dumy, P.; Marra, A. *New J. Chem.* **2015**, *30*, 5050-5074.

<sup>[1]</sup> Pieters, R. J. Org. Biomol. Chem., 2009, 7, 2013–2025.